Combining antibody drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) targeting HER2 has been shown to improve efficacy in patients with advanced HER2+ breast cancer. Here, the authors report a randomised phase 2b trial comparing neoadjuvant ARX788 (HER2 ADC) plus pyrotinib (HER1, HER2 and HER4 TKI) against neoadjuvant standard of care (docetaxel, carboplatin, trastuzumab, and pertuzumab) for the treatment of HER2+ breast cancer.
- Nan Niu
- Jinqi Xue
- Caigang Liu
